73 Percent of Retail Applications Contain Security Flaws, but Only a Quarter Are Fixed
Veracode, a leading global provider of modern application security testing solutions, today revealed that almost three-quarters of applications in the retail & hospitality sector contain security flaws, but only 25 percent of these are fixed. Furthermore, 17 percent of these flaws are categorized as ‘high severity’, meaning they pose a serious risk to the business if exploited. With 76 percent of Americans planning to shop the Black Friday sales on 25 November*—and 56 percent planning to purchase entirely online**— retailers should take extra care to reinforce the security of their ecommerce systems, digital payment platforms, and supply chains.
The data was published in Veracode’s annual State of Software Security (SoSS) report v12, which analyzed 20 million scans across half a million applications in the retail, manufacturing, healthcare, financial services, technology, and government sectors.
Chris Eng, Chief Research Officer at Veracode, said, “Maintaining customer loyalty and trust is priority number one for retailers, and this will be heightened during the Black Friday period. With the average cost of a data breach in the retail sector calculated at $3.28 million***, implementing robust tools and practices to secure the applications customers use to browse and make purchases is imperative.”
Despite the relatively low number of flaws that are fixed, the retail industry takes second place for overall remediation rate, highlighting the need for software security improvements from organizations across all sectors. Eng said, “Compared with other sectors, retailers are better at fixing flaws when they’re discovered. While this is encouraging, it’s clear more needs to be done across the board to integrate flaw identification and remediation into the software development pipeline so that vulnerabilities can be addressed more efficiently.”
Server configuration, insecure dependencies, and authentication issues are the most common types of application flaws across most industries. The retail & hospitality sector follows a similar pattern; however, the sector has higher percentages in nearly every flaw category—perhaps due to the greater functional complexity of customer-facing and back-office applications.
Flaw Fix Times Fluctuate in Retail
Veracode analyzed three different scan types to generate industry comparisons for fix times: dynamic analysis security testing (DAST), static analysis security testing (SAST), and software composition analysis (SCA). Retailers were found to be the quickest to address flaws discovered by DAST, at 70 days to reach the halfway point, which is a staggering 46 days faster than financial services in second place. When it came to SAST and SCA, however, the retail sector fell to the middle of the pack, taking 346 days and 470 days respectively to reach the halfway fix point.
Across all industries, flaws in third-party libraries discovered through SCA persist for longer than those found through SAST and DAST, with 30 percent of vulnerable libraries still unresolved after two years. For the retail sector, that statistic rises to 35 percent and lags the cross-industry average by more than six months. Nevertheless, retailers should be assured that the gap is never too wide to close. Indeed, Veracode’s 2021 State of Software Security report found 92 percent of open-source flaws can be easily fixed with a simple update, which is good news for retailers looking to secure their software supply chains.
In the run-up to Black Friday, and nearly one year since the infamous Log4j vulnerability was first reported, retailers will be on high alert to maintain the speed, efficiency, and security of their applications. Businesses should take extra care to uncover vulnerabilities in third-party software using a combination of SCA and development tools. Using this approach with Veracode, Darius Radford, Application Security Architect at specialty retailer Floor & Decor, was able to get a comprehensive view of risk posed by vulnerable libraries in the company’s software: “We were able to quickly figure out all the places running Log4j and remediate the situation.” Trey Tunnel, Floor and Decor’s Chief Information Security Officer, added, “Our customers are our top priority. With Veracode, we have the confidence that our software is secure and—more importantly—our customers have the confidence that our software is secure.”
The Veracode State of Software Security v12 retail & hospitality snapshot is available to download here and the full report is available here.
* Future Publishing, “Exploring the impact of rising inflation”, June 2022, https://go.future-advertising.com/Rising-Inflation-Research-Insights.html
** Dot Digital, “Black Friday Stats: Everything You Need to Know (updated 2022), Jenna Paton, 20 September 2022, https://dotdigital.com/blog/black-friday-cyber-monday-stats/
*** IBM Security and The Ponemon Institute, “Cost of a Data Breach Report 2022”, July 2022, https://www.ibm.com/downloads/cas/3R8N1DZJ
About the State of Software Security Report
The Veracode State of Software Security (SoSS) v12 analyzed the full historical data from Veracode services and customers. This accounts for a total of more than half a million applications (592,720) that used all scan types, more than a million dynamic analysis scans (1,034,855), more than five million static analysis scans (5,137,882) and more than 18 million software composition analysis scans (18,473,203). All those scans produced 42 million raw static findings, 3.5 million raw dynamic findings, and six million raw SCA findings.
The data represents large and small companies, commercial software suppliers, software outsourcers, and open-source projects. In most analyses, an application was counted only once, even if it was submitted multiple times as vulnerabilities were remediated, and new versions uploaded.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005446/en/
Contact information
Katy Gwilliam
kgwilliam@veracode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
